| 1. |
-
- 2019
-
Tidskriftsartikel (refereegranskat)
|
|
| 2. |
|
|
| 3. |
- Auffray, Charles, et al.
(författare)
-
Making sense of big data in health research: Towards an EU action plan
- 2016
-
Ingår i: Genome Medicine. - : BIOMED CENTRAL LTD. - 1756-994X. ; 8:71
-
Tidskriftsartikel (refereegranskat)abstract
- Medicine and healthcare are undergoing profound changes. Whole-genome sequencing and high-resolution imaging technologies are key drivers of this rapid and crucial transformation. Technological innovation combined with automation and miniaturization has triggered an explosion in data production that will soon reach exabyte proportions. How are we going to deal with this exponential increase in data production? The potential of "big data" for improving health is enormous but, at the same time, we face a wide range of challenges to overcome urgently. Europe is very proud of its cultural diversity; however, exploitation of the data made available through advances in genomic medicine, imaging, and a wide range of mobile health applications or connected devices is hampered by numerous historical, technical, legal, and political barriers. European health systems and databases are diverse and fragmented. There is a lack of harmonization of data formats, processing, analysis, and data transfer, which leads to incompatibilities and lost opportunities. Legal frameworks for data sharing are evolving. Clinicians, researchers, and citizens need improved methods, tools, and training to generate, analyze, and query data effectively. Addressing these barriers will contribute to creating the European Single Market for health, which will improve health arid healthcare for all Europearis.
|
|
| 4. |
- Baigent, Colin, et al.
(författare)
-
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial
- 2011
-
Ingår i: The Lancet. - 0140-6736 .- 1474-547X. ; 377:9784, s. 2181-2192
-
Tidskriftsartikel (refereegranskat)abstract
- Background Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients. Methods This randomised double-blind trial included 9270 patients with chronic kidney disease (3023 on dialysis and 6247 not) with no known history of myocardial infarction or coronary revascularisation. Patients were randomly assigned to simvastatin 20 mg plus ezetimibe 10 mg daily versus matching placebo. The key prespecified outcome was first major atherosclerotic event (non-fatal myocardial infarction or coronary death, non-haemorrhagic stroke, or any arterial revascularisation procedure). All analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, NCT00125593, and I SRCTN54137607. Findings 4650 patients were assigned to receive simvastatin plus ezetimibe and 4620 to placebo. Allocation to simvastatin plus ezetimibe yielded an average LDL cholesterol difference of 0.85 mmol/L (SE 0.02; with about two-thirds compliance) during a median follow-up of 4.9 years and produced a 17% proportional reduction in major atherosclerotic events (526 [11.3%] simvastatin plus ezetimibe vs 619 [13.4%] placebo; rate ratio [RR] 0.83, 95% CI 0.74-0.94; log-rank p=0.0021). Non-significantly fewer patients allocated to simvastatin plus ezetimibe had a non-fatal myocardial infarction or died from coronary heart disease (213 [4.6%] vs 230 [5.0%]; RR 0.92,95% CI 0.76-1.11; p=0.37) and there were significant reductions in non-haemorrhagic stroke (131 [2.8%] vs 174 [3.8%]; RR 0.75,95% CI 0.60-0.94; p=0.01) and arterial revascularisation procedures (284 [6.1%] vs 352 [7.6%]; RR 0.79, 95% CI 0.68-0.93; p=0.0036). After weighting for subgroup-specific reductions in LDL cholesterol, there was no good evidence that the proportional effects on major atherosclerotic events differed from the summary rate ratio in any subgroup examined, and, in particular, they were similar in patients on dialysis and those who were not. The excess risk of myopathy was only two per 10 000 patients per year of treatment with this combination (9 [0.2%] vs 5 [0.1%]). There was no evidence of excess risks of hepatitis (21 [0.5%] vs 18 [0.4%]), gallstones (106 [2.3%] vs 106 [2.3%]), or cancer (438 [9.4%] vs 439 [9.5%], p=0.89) and there was no significant excess of death from any non-vascular cause (668 [14.4%] vs 612 [13.2%], p=0.13). Interpretation Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.
|
|
| 5. |
- Grimm, Alejandro, et al.
(författare)
-
Slagging and fouling characteristics during co-combustion of Scots pine bark with low-temperature dried pulp and paper mill chemical sludge
- 2019
-
Ingår i: Fuel processing technology. - : Elsevier. - 0378-3820 .- 1873-7188. ; 193, s. 282-294
-
Tidskriftsartikel (refereegranskat)abstract
- This paper shows how chemical sludge (CS) generated during wastewater treatment at a paperboard mill can be quickly dried at low-temperature and employed in bark-fired boilers to reduce slagging and corrosion problems. By using a cyclone-dryer operated at an inlet-air velocity of 110 m/s and a temperature of 90 degrees C, the dry-matter content of CS was increased from approximately 19 to 82%. The residence time of CS inside the cyclone was approximately 2 s when using the inlet-air velocity mentioned above. Disaggregation of the feedstock caused by collisions with the cyclone wall and between particles played a crucial role in enhancing the efficiency of heat and mass transfer. Three co-pelletized mixtures of Scots pine bark (SPB) and dried-CS were combusted in a 40 kW fixed-bed burner. Flue gas analysis was performed with a gas analyser. Coarse and fine ash were analysed by SEM-EDS and XRD. NOx, and SO2 emissions increased with increasing amount of CS in the mixtures. Mono combustion of SPB resulted in a large quantity of slag (i.e., molten ash) with a high degree of sintering (i.e., hardness of the slag), and ash deposits formed on heat transfer surfaces were rich in K2SO4 and KCI. Mixtures of SPB and CS were less prone to slagging, and the amount of alkali chloride in the deposits was reduced in favour of alkali sulphate formation.
|
|
| 6. |
- Grimm, Christoph, et al.
(författare)
-
C-Based Design of Embedded Systems - Editorial
- 2008
-
Ingår i: EURASIP Journal on Embedded Systems. - : Springer Science and Business Media LLC. - 1687-3955 .- 1687-3963. ; :1, s. 243890-
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 7. |
|
|
| 8. |
- Herrholz, Andreas, et al.
(författare)
-
The ANDRES Project : Analysis and Design of run-time Reconfigurable, heterogeneous Systems
- 2007
-
Ingår i: Proceedings - 2007 International Conference on Field Programmable Logic and Applications, FPL. - : IEEE. - 9781424410606 - 1424410606 ; , s. 396-401
-
Konferensbidrag (refereegranskat)abstract
- Today's heterogeneous embedded systems combine components from different domains, such as software, analogue hardware and digital hardware. The design and implementation of these systems is still a complex and error-prone task due to the different Models of Computations (MoCs), design languages and tools associated with each of the domains. Though making such systems adaptive is technologically feasible, most of the current design methodologies do not explicitely support adaptive architectures. This paper present the ANDRES project. The main objective of ANDRES is the development of a seamless design flow for adaptive heterogeneous embedded systems (AHES) based on the modelling language SystemC. Using domain-specific modelling extensions and libraries, ANDRES will provide means to efficiently use and exploit adaptivity in embedded system design. The design flow is completed by a methodology and tools for automatic hardware and software synthesis for adaptive architectures.
|
|
| 9. |
- Machleid, Rafael, et al.
(författare)
-
Feasibility and performance of cross-clone Raman calibration models in CHO cultivation
- 2024
-
Ingår i: Biotechnology Journal. - : John Wiley & Sons. - 1860-6768 .- 1860-7314. ; 19:1
-
Tidskriftsartikel (refereegranskat)abstract
- Raman spectroscopy is widely used in monitoring and controlling cell cultivations for biopharmaceutical drug manufacturing. However, its implementation for culture monitoring in the cell line development stage has received little attention. Therefore, the impact of clonal differences, such as productivity and growth, on the prediction accuracy and transferability of Raman calibration models is not yet well described. Raman OPLS models were developed for predicting titer, glucose and lactate using eleven CHO clones from a single cell line. These clones exhibited diverse productivity and growth rates. The calibration models were evaluated for clone-related biases using clone-wise linear regression analysis on cross validated predictions. The results revealed that clonal differences did not affect the prediction of glucose and lactate, but titer models showed a significant clone-related bias, which remained even after applying variable selection methods. The bias was associated with clonal productivity and lead to increased prediction errors when titer models were transferred to cultivations with productivity levels outside the range of their training data. The findings demonstrate the feasibility of Raman-based monitoring of glucose and lactate in cell line development with high accuracy. However, accurate titer prediction requires careful consideration of clonal characteristics during model development.
|
|
| 10. |
- Michalon, Aubin, et al.
(författare)
-
A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells
- 2021
-
Ingår i: Nature Communications. - : Nature Publishing Group. - 2041-1723. ; 12:1
-
Tidskriftsartikel (refereegranskat)abstract
- Transthyretin amyloid (ATTR) cardiomyopathy is a debilitating disease leading to heart failure and death. It is characterized by the deposition of extracellular ATTR fibrils in the myocardium. Reducing myocardial ATTR load is a therapeutic goal anticipated to translate into restored cardiac function and improved patient survival. For this purpose, we developed the selective anti-ATTR antibody NI301A, a recombinant human monoclonal immunoglobulin G1. NI301A was cloned following comprehensive analyses of memory B cell repertoires derived from healthy elderly subjects. NI301A binds selectively with high affinity to the disease-associated ATTR aggregates of either wild-type or variant ATTR related to sporadic or hereditary disease, respectively. It does not bind physiological transthyretin. NI301A removes ATTR deposits ex vivo from patient-derived myocardium by macrophages, as well as in vivo from mice grafted with patient-derived ATTR fibrils in a dose- and time-dependent fashion. The biological activity of ATTR removal involves antibody-mediated activation of phagocytic immune cells including macrophages. These data support the evaluation of safety and tolerability of NI301A in an ongoing phase 1 clinical trial in patients with ATTR cardiomyopathy.
|
|
